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Acetylcholine activates nicotinic acetylcholine receptors (nAChRs) by binding at an extracellular
orthosteric site. Previous studies have described several positive allosteric modulators (PAMs) that are
selective for homomeric a7 nAChRs. These include type I PAMs, which exert little or no effect on the rate
of receptor desensitisation, and type II PAMs, which cause a dramatic loss of agonist-induced desensi-
tisation. Here we report evidence that transmembrane mutations in a7 nAChRs have diverse effects on
receptor activation and desensitisation by allosteric ligands. It has been reported previously that the
L247T mutation, located toward the middle of the second transmembrane domain (at the 90 position),
confers reduced levels of desensitisation. In contrast, the M260L mutation, located higher up in the TM2
domain (at the 220 position), does not show any difference in desensitisation compared to wild-type
receptors. We have found that in receptors containing the L247T mutation, both type I PAMs and type
II PAMs are converted into non-desensitising agonists. In contrast, in receptors containing the M260L
mutation, this effect is seen only with type II PAMs. These ﬁndings, indicating that the M260L mutation
has a selective effect on type II PAMs, have been conﬁrmed both with previously described PAMs and also
with a series of novel a7-selective PAMs. The novel PAMs examined in this study have close chemical
similarity but diverse pharmacological properties. For example, they include compounds displaying ef-
fects on receptor desensitisation that are typical of classical type I and type II PAMs but, in addition, they
include compounds with intermediate properties.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
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Nicotinic acetylcholine receptors (nAChRs) are transmembrane
receptors that are activated by the neurotransmitter acetylcholine.
They are members of a structurally related family of pentameric
ligand-gated ion channels that also includes receptors for neuro-
transmitters such as 5-hydroxytryptamine (5-HT), g-aminobutyric
acid (GABA), and glycine (Changeux, 2012; Lester et al., 2004). In
common with other members of this family, the conventional
‘orthosteric’ agonist-binding site of nAChRs is located at an extra-
cellular location at the interface of two adjacent subunits (Arias,
2000; Unwin, 2005).
Nicotinic receptors are present at the neuromuscular junction
where they mediate muscle contraction (muscle-type nAChRs) and
also within the central and peripheral nervous system (neuronal
nAChRs), where they have a variety of roles, including mediatingunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Chemical structures of the allosteric modulators examined in this study.
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transmitters (Albuquerque et al., 2009; Gotti et al., 2009). Seven-
teen subunits have been identiﬁed in vertebrates (a1-10, b1-4, g,
d and ε), which co-assemble to form a diverse family of receptor
subtypes (Millar and Gotti, 2009). Whereas most nAChRs are het-
eromeric combinations of more than one type of subunit (Millar
and Gotti, 2009), some nAChRs, such as a7, are able to form func-
tional homomeric nAChRs (Couturier et al., 1990). Homomeric a7
nAChRs are somewhat atypical in that they undergo very rapid
desensitisation in response to agonist activation. Indeed, with high
concentrations of acetylcholine, almost complete inactivation of a7
nAChRs is observed within milliseconds of agonist activation
(Couturier et al., 1990). However, rapid desensitisation of a7
nAChRs is not seen with all agonists. A group of compounds,
described as allosteric agonists, activate a7 nAChRs with minimal
levels of desensitisation (Gill et al., 2012, 2011; Papke et al., 2014). In
contrast to conventional orthosteric agonists such as acetylcholine,
there is evidence that allosteric agonists may act via a distinct
transmembrane binding site (Gill et al., 2011).
Previous studies have identiﬁed an extensive series of com-
pounds that lack agonist activity on a7 nAChRs but which
potentiate agonist-evoked responses (Faghih et al., 2008;
Williams et al., 2011). Such compounds are described as posi-
tive allosteric modulators (PAMs) and, in the case of those acting
on a7 nAChRs, have been referred to as either ‘type I’ or ‘type II’
PAMs, depending on their effects on receptor desensitisation
(Bertrand and Gopalakrishnan, 2007). The convention is to
describe PAMs with little or no signiﬁcant effect on desensiti-
sation as type I PAMs and those causing a dramatic reduction in
desensitisation as type II PAMs. In addition, there is evidence
that relatively small changes in chemical structure of allosteric
modulators acting on a7 nAChRs can have a dramatic effect on
pharmacological properties. For example, altering methyl sub-
stitution on a single aromatic ring, which can also alter stereo-
chemistry, has been reported to convert PAMs into negative
allosteric modulators, silent allosteric modulators or allosteric
agonists (Gill-Thind et al., 2015).
Neuronal nAChRs have been implicated in a variety of cognitive
and neurological disorders, including Alzheimer's disease, Parkin-
son's disease, epilepsy and schizophrenia (Changeux and Taly,
2008; Weiland et al., 2000) and, as a consequence, are targets for
therapeutic drug development. A number of subtype-selective
orthosteric agonists, partial agonists and antagonists have been
developed (Gündisch and Eibl, 2011), but it has been argued that
compounds binding to allosteric sites may provide an opportunity
for greater receptor subtype selectivity (Williams et al., 2011).
Indeed promising results have been obtained in pre-clinical studies
with nAChR allosteric modulators in studies examining effects on
cognitive deﬁcits (Hurst et al., 2005; Ng et al., 2007; Timmermann
et al., 2007), nociception (Munro et al., 2012; Zhu et al., 2011) ce-
rebral ischaemia (Kalappa et al., 2013) and depression (Targowska-
Duda et al., 2014).
Here, we describe studies with a7 nAChRs containing one of
two point mutations in the second transmembrane domain (TM2)
and we examine the effect of these mutations on receptor acti-
vation and desensitisation. Introduction of a single point mutation
(L247T) in the 90 position of TM2 of the a7 nAChR has been re-
ported previously to exert dramatic and diverse effects on the
functional properties of this receptor (Bertrand et al., 1992; Revah
et al., 1991). The effects of the L247T mutation include increased
potency of agonists such as acetylcholine and reduced levels of
desensitisation (Bertrand et al., 1992; Revah et al., 1991). In
contrast, the M260L mutation, located higher up in TM2 (at the 220
position), does not result in any difference in receptor desensiti-
sation compared to wild-type receptors. Here, we haveinvestigated the effects of these mutations on receptor activation
using a variety of PAMs, including a series of novel compounds
containing a substituted triazole group. We conclude that multiple
transmembrane mutations in a7 nAChRs can convert PAMs into
allosteric agonists. In addition, it appears that the M260L mutation
has a selective effect on PAMs that reduce agonist-evoked
desensitisation (type II PAMs).
2. Materials and methods
2.1. Chemical synthesis
As is described in more detail in the Supporting information, the following
compounds were prepared by a modiﬁcation of a literature procedure for triazole
synthesis (El Kaim et al., 2010): 4-(3-(4-bromophenyl)-5-phenyl-1H-1,2,4-triazol-1-
yl)benzenesulfonamide (TBS-345), 4-(3-(4-bromophenyl)-5-(4-methoxyphenyl)-
1H-1,2,4-triazol-1-yl)benzenesulfonamide (TBS-346), 4-(5-benzyl-3-(4-
bromophenyl)-1H-1,2,4-triazol-1-yl)benzenesulfonamide (TBS-516), 4-(3-(4-
bromophenyl)-5-propyl-1H-1,2,4-triazol-1-yl)benzenesulfonamide (TBS-546) and
4-(3-(4-bromophenyl)-5-phenethyl-1H-1,2,4-triazol-1-yl)benzenesulfonamide
(TBS-556). Synthesis of cis-cis-4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclo-
penta[c]quinoline-8-sulfonamide (4BP-TQS) and cis-cis-4-(napthalen-1-yl)-
3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide (TQS) has been
described previously (Gill et al., 2012). NS-1738 was obtained from Tocris Bioscience.
2.2. Plasmids
All plasmid constructs used in this study have been described previously. These
include plasmids containing cDNAs encoding human a3, a4, a7, b2 and b4 nAChR
Fig. 2. Potentiation of responses to acetylcholine on wild-type a7 nAChRs by TBS
compounds. Representative traces are shown illustrating responses to acetylcholine
(100 mM) together with responses from the same oocyte to acetylcholine (100 mM)
after pre- and co-application of 10 mM TBS-346 (A), TBS-546 (B), TBS-345 (C), TBS-556
(D) or TBS-516 (E).
A. Chatzidaki et al. / Neuropharmacology 97 (2015) 75e85 77subunits in pSP64GL (Broadbent et al., 2006); rat a7 nAChR subunit in pcDNA3
(Cooper and Millar, 1997); a7/5-HT3A subunit chimera (containing the rat a7 N-
terminal domain and mouse 5-HT3A transmembrane and C-terminal domain) in
pcDNA3 (Cooper and Millar, 1998); human RIC-3 in pRK5 (Lansdell et al., 2005) and
mouse 5-HT3A (Maricq et al., 1991) in pRK5.
2.3. Site-directed mutagenesis and cRNA synthesis
Site-directed mutagenesis was performed on human nAChR a7 subunit cDNA in
plasmid pSP64GL using the QuikChange mutagenesis kit (Stratagene) and veriﬁed
by nucleotide sequencing. Plasmid pSP64GL containing wild-type or mutated hu-
man a7 cDNAwas linearizedwith BamHI and puriﬁed with QIAQuik PCR puriﬁcation
kit (Qiagen). In vitro synthesis of cRNA was performed using mMessage mMachine
SP6 transcription kit (Life Technologies). For consistency with previous studies, the
numbering of amino acids altered by site-directed mutagenesis is based on the
predicted signal sequence cleavage site in the mature a7 protein (Couturier et al.,
1990).
2.4. Oocyte electrophysiology
Oocytes were isolated from adult female Xenopus laevis following procedures
that have been approved by UCL's Biological Services Management Group and the
UK Home Ofﬁce. Oocytes were defolliculated as described previously (Young et al.,
2007) by treatment with collagenase (2 mg/ml; Worthington Biochemicals, Free-
hold, NJ) in calcium-free Barth's solution containing 88 mM NaCl, 2.4 mM NaHCO3,Table 1
Properties (potentiation or inhibition) of TBS compounds on nAChR and 5-HT3AR subtyp
Receptor TBS-345 TBS-346 TBS-51
Fold
potentiation
% Inhibition Fold
potentiation
% Inhibition Fold
potenti
Human a7 8.8 ± 1.5 e 10.5 ± 2.5 e 11.3 ±
Human a4b2 e 20.1 ± 19.0 e 23.1 ± 5.7 e
Human a3b4 e 53.7 ± 18.3 e 68.4 ± 3.0 e
Rat a7 10.9 ± 0.73 e 8.7 ± 5.3 e 3.6 ± 1
Mouse 5-HT3A e 18.3 ± 13.3 e 30.8 ± 15.5 e
Chimeraa e 47.3 ± 10.1 e 13.4 ± 7.7 e
Data are means ± SEM from at least three independent experiments.
a Chimeric subunit containing the rat nAChR a7 subunit N-terminal domain and mou1 mM KCl, 0.82 mM MgSO4, and 15 mM Tris, pH 7.5. Heterologous expression was
achieved by injection of wild-type or mutated a7 cRNA (6e12 ng) into oocyte
cytoplasm. Oocytes were injected in a volume of 20e30 nl using a Drummond
variable volume microinjector. After injection, oocytes were incubated at 18 C in a
calcium-containing Barth's solution (composition, as above, but with 0.77 mM
CaCl2) supplemented with antibiotics (100 units/ml penicillin, 100 mg/ml strepto-
mycin, 4 mg/ml kanamycin, and 50 mg/ml tetracycline). Experiments were performed
on oocytes after 3e5 days of incubation. Oocytes were placed in a recording
chamber and continuously perfused with a saline solution (115 mM NaCl, 2.5 mM
KCl, 1.8 mM BaCl2, and 10 mM HEPES, pH 7.3) with a ﬂow rate of approximately
15 ml/min. Two-electrode voltage-clamp recordings were performed (with the
oocyte membrane potential held at 60 mV), as described previously (Gill et al.,
2012; Young et al., 2007).
2.5. Radioligand binding
Human kidney tsA201 cells were cultured in Dulbecco's modiﬁed Eagle's
medium (Invitrogen Life Technologies) containing 10% foetal calf serum (Sigma),
penicillin (100 U/ml) and streptomycin (100 mg/ml) (Invitrogen Life Technolo-
gies). Cells were maintained in a humidiﬁed incubator containing 5% CO2 at
37 C. Cells were transfected with human a7 nAChRs and human RIC-3 in 1:1
ratio using the Effectene reagent (Qiagen, Crawley, UK) according to the manu-
facturer's instructions. After overnight incubation in Effectene, cells were incu-
bated at 37 C for 24e48 h before being assayed for radioligand binding with
[3H]-a-bungarotoxin (56 Ci/mmol; Tocris Bioscience, Bristol, UK). Radioligand
binding to transiently transfected tsA201 cells was performed essentially as
described previously (Lansdell and Millar 2004). Transfected cells were re-
suspended in Hank's buffered saline solution (Gibco, Paisley, UK) containing 1%
bovine serum albumin and incubated with [3H]-a-bungarotoxin for 2 h at 22 C
in a total volume of 150 mL. Non-speciﬁc binding was determined in the presence
of nicotine (1 mM) and carbamylcholine (1 mM). Competition binding experi-
ments were performed by incubating triplicate samples of transfected cells with
[3H]-a-bungarotoxin (1 nM), together with a range of concentrations of either
PAMs or methyllycaconitine (MLA). Radioligand binding was assayed by ﬁltration
onto Whatman GF/A ﬁlters (pre-soaked in 0.5% polyethylenimine), followed by
rapid washing with phosphate-buffered saline (Oxoid, Basingstoke, UK) using a
Brandel cell harvester. Bound radioligand was quantiﬁed by scintillation count-
ing. Curves for equilibrium binding were ﬁtted using GraphPad Prism (GraphPad
Software, San Diego, CA, USA).
2.6. Statistical analysis
For pairwise comparisons, statistical signiﬁcance was determined by unpaired
Student's t-tests.
3. Results
3.1. A novel series of a7 nAChR-selective PAMs
A novel series of compounds (Fig. 1) was constructed involving a
combination of structural elements from two previously described
a7-selective allosteric modulators, 4BP-TQS (Gill et al., 2011) and
A867744 (Faghih et al., 2008). Both 4BP-TQS and A867744 contain
an arylsulfonamide unit linked to a heterocyclic core, which has
both a bromoarene and a second lipophilic group attached. Five
compounds were synthesised which retained the key structural
features of 4BP-TQS and A867744 but which contained amore polar
triazole group as the heterocyclic core. For convenience, thesees.
6 TBS-546 TBS-556
ation
% Inhibition Fold
potentiation
% Inhibition Fold
potentiation
% Inhibition
3.1 e 4.7 ± 1.0 e 4.7 ± 0.2 e
1.7 ± 0.4 e 20.5 ± 5.9 e 3.2 ± 0.9
31.1 ± 0.6 e 9.0 ± 3.5 e 16 ± 13
.0 e 1.9 ± 0.2 e 4.3 ± 0.6 e
10.4 ± 7.5 e 15.2 ± 4.3 e 10 ± 1.9
9.2 ± 12.8 e 26.4 ± 16.0 e 1.0 ± 1.0
se 5-HT3A subunit transmembrane and C-terminal domain.
Fig. 3. Inﬂuence of TBS compounds on the recovery of a7 nAChRs from desensitisation.
Representative traces showing prolonged exposure of a7 nAChRs to acetylcholine
(100 mM), causing activation, followed by rapid desensitisation. In the continued
presence of acetylcholine, application of (A) TBS-346 (10 mM) and (B) TBS-546 (10 mM)
does not result in reactivation of the receptor. However, application of (C) TBS-345
(10 mM), (D) TBS-556 (10 mM) and (E) TBS-516 (10 mM) results in reactivation of
desensitised receptors. Traces have been scaled to their response to acetylcholine.
A. Chatzidaki et al. / Neuropharmacology 97 (2015) 75e8578compounds are referred to here collectively as ‘TBS’ compounds to
reﬂect the fact that they all contain triazole and benzenesulfona-
mide groups.
None of the TBS compounds examined displayed agonist ac-
tivity when applied alone to human a7 nAChRs expressed in
Xenopus oocytes but all of them potentiated responses evoked by
acetylcholine (Fig. 2). The maximum fold potentiation by the TBS
compounds of responses to an EC50 of acetylcholine (100 mM) isshown in Table 1. Notably, despite the relatively close chemical
similarity between these compounds, they displayed a diverse
range of effects on the rate of desensitisation of a7 nAChRs. For
example, TBS-346 caused minimal changes to desensitisation, a
feature that is typical of type I PAMs, whereas TBS-516 caused a
dramatic slowing of desensitisation, typical of type II PAMs (Fig. 2).
In addition, other compounds in this series (TBS-345, TBS-546 and
TBS-556) had effects on receptor desensitisation that could be
considered as being intermediate between those of classical type I
and type II PAMs (Fig. 2). Another property of type II PAMs is their
ability to reactivate a7 nAChRs after they have been desensitised
by continuous application of an orthosteric agonist (Hurst et al.,
2005), while type I PAMs lack this ability (Grønlien et al., 2007).
Fig. 3 demonstrates the effect of TBS compounds on the recovery
from desensitisation of a7 nAChRs after activation and desensiti-
sation by an EC50 of acetylcholine (100 mM). TBS-346 and TBS-546
elicited no detectable responses after the receptor had been
desensitised, a feature that is characteristic of type I PAMs. In
contrast, TBS-345, TBS-516 and TBS-556 caused recovery from
desensitisation, albeit to differing extents (Fig. 3). TBS-516 had the
most profound effect, by eliciting a response that was 3.2 ± 0.9 e
fold larger than the response to 100 mM acetylcholine. TBS-556
and TBS-345 elicited responses that were 57.3 ± 10.1% and
23.0 ± 2.1% of the response to 100 mM acetylcholine, respectively
(Fig. 3). Where receptor reactivation was observed (when acetyl-
choline was co-applied with TBS-345, TBS-556 or TBS-516), no
desensitisation was observed over a period 30 s (Fig. 3). The total
net charge transfer, measured during a 30 s application of TBS-
345, TBS-556 and TBS-516 was 12 ± 2, 27 ± 6 and 250 ± 71 fold
larger than that measured during the initial application, of
acetylcholine alone (Fig. 3).
Competition radioligand binding was performed to examine the
ability of the TBS compounds to displace [3H]-a-bungarotoxin from
the orthosteric binding site of a7 nAChRs (Fig. 4). In order to more
easily obtain sufﬁcient amounts of a7 nAChR, radioligand binding
assays were performed with recombinant receptors expressed in a
cultured cell line (human kidney tsA201 cells) rather than in Xen-
opus oocytes, which were used for electrophysiological studies. As
expected, the competitive antagonist MLA fully displaced speciﬁc
[3H]-a-bungarotoxin binding in a concentration-dependent
manner (Fig. 4). In contrast, none of the TBS compounds dis-
played any signiﬁcant displacement of [3H]-a-bungarotoxin bind-
ing (Fig. 4). These ﬁndings are consistent with TBS compounds
acting as potentiators of a7 nAChRs via a site other than the
extracellular orthosteric binding site.
All of the TBS compounds acted as potentiators of both human
and rat a7 nAChRs (Table 1). In contrast, none of the TBS com-
pounds caused potentiation of human a4b2 nAChRs, human a3b4
nAChRs or mouse 5-HT3ARs. Instead, all of the compounds acted
as inhibitors of this diverse group of receptors (Table 1), indi-
cating that, to the extent that we have examined, these TBS
compounds can be considered to be a7-selective PAMs. The
opposing effects of the TBS compounds on a7 nAChRs and 5-
HT3ARs (potentiation and inhibition, respectively) prompted us
to examine the effect of these compounds on an artiﬁcial subunit
chimera (a7/5-HT3A) containing the extracellular/N-terminal
domain of the rat a7 nAChR subunit and the transmembrane/C-
terminal domain of the mouse 5-HT3A subunit. For all of the
TBS compounds examined, inhibition of agonist-evoked re-
sponses was observed on the a7/5-HT3A subunit chimera
(Table 1). Together, these results are consistent with these com-
pounds interacting with the transmembrane domain, a location
that has been proposed as being the site at which several other
a7-selective PAMs interact with a7 nAChRs (Collins et al., 2011;
Gill et al., 2011; Young et al., 2008).
Fig. 4. Competition radioligand binding. Equilibrium radioligand binding was per-
formed with [3H]-a-bungarotoxin (1 nM) with mammalian tsA201 cells transiently
transfected with human a7 nAChR subunit and with human RIC-3 cDNAs (1:1 ratio).
TBS-345, TBS-346, TBS-516, TBS-546 and TBS-556 caused no signiﬁcant displacement
of [3H]-a-bungarotoxin binding, whereas MLA caused complete displacement of spe-
ciﬁc radioligand binding. Data points are means of triplicate samples (± SD) from a
single experiment, and data are typical of three independent experiments.
Fig. 5. The inﬂuence of a7 nAChR mutations (L247T and M260L) on activation by
acetylcholine. A) The location of L247T (90) and M260L (220) mutations in the a7 nAChR
subunit transmembrane (TM2) domain. The transmembrane region of an a7 nAChR
subunit homology model (Young et al., 2008) is shown viewed from the top (left hand
image) and from the side (right hand image). The a-helical transmembrane regions are
illustrated as ribbon structures with the side chains of the two mutated amino acids
shown as space-ﬁlling models (L247 in red and M260 in blue). B) Representative traces
are shown illustrating responses to maximal concentrations of acetylcholine on human
wild-type (WT) a7 nAChRs and a7 nAChRs containing the M260L mutation (M260L)
and the L247T mutation (L247T). Acetylcholine concentrations: 1 mM for WT and
M260L and 10 mM for L247T. C) Acetylcholine concentration-response data are pre-
sented for wild-type a7 nAChRs (triangles) and for a7 nAChRs containing either the
M260L mutation (circles) or the L247T mutation (diamonds). Data are means ± SEM of
at least three independent experiments and are normalised to the respective
maximum response obtained with each nAChR variant. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)
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There are several examples of individual point mutations in
nAChR subunits that result in dramatic effects on the pharmaco-
logical properties of receptors. For example, in agreement with
previous studies (Revah et al., 1991), a single point mutation
(L247T), located towards the middle of the second transmembrane
(TM2) domain (at the 90 position) of the a7 subunit (Fig. 5A) causes
a dramatic slowing of receptor desensitisation and a large leftward
shift (660-fold; t(7) ¼ 7.1, P < 0.001,) of the concentration-response
curve for acetylcholine (Fig. 5B and C). In contrast, another point
mutation (M260L), located towards the top of TM2 (at the 220 po-
sition) (Fig. 5A) was found to have little or no effect on the rate of
receptor desensitisation after activation by acetylcholine and
caused a much smaller leftward shift (2.1-fold; t(5) ¼ 3.1, P ¼ 0.03)
in the acetylcholine concentrationeresponse curve (Fig. 5 and
Table 2).
We have observed further differences between wild-type and
mutated (L247T and M260L) a7 nAChRs in the extent to which they
are modulated by type I and type II PAMs. Initially, studies were
conducted with two previously described ‘classical’ type I and type
II PAMs (NS-1738 and TQS, respectively). As is illustrated, both
compounds lack agonist effects on wild-type a7 nAChRs but both
potentiate agonist-evoked responses on wild-type receptors
(Fig. 6A). In agreement with previous studies (Grønlien et al., 2007;
Timmermann et al., 2007), NS-1738 caused potentiation of agonist-
evoked responses with little or no effect on desensitisation,
whereas TQS results in a dramatic loss of desensitisation (Fig. 6A).
As has been reported previously (Gill et al., 2011), one of the
effects of the L247T mutation is that it converts the type II PAM TQS
into a potent agonist of the mutated receptor. Here we have shown
that a similar effect (the conversion of a PAM into an agonist) is also
observed with NS-1738, a classical type I PAM (Fig. 6B). In contrast
to L247T, the M260L mutation had a selective effect on these two
PAMs. As had been observed with L247T, TQS (a type II PAM) acted
as a non-desensitising agonist on receptors containing the M260L
mutation, whereas NS-1738 (a type I PAM) had no agonist activity
on this mutated receptor (Fig. 6C). Thus, the two TM2 mutations
(L247T and M260L) have differing effects on desensitisation of a7nAChRs, when activated by acetylcholine (Fig. 5) and also differ in
their ability to convert the type I PAM into an agonist (Fig. 6).
However, they share an ability to convert the type II PAM into an
agonist (Fig. 6).
Table 2
Agonist properties on wild-type and mutated a7 nAChRs.
Receptor Agonist EC50 (mM) nH Imaxa
Wild-type a7 Acetylcholine 132 ± 13 1.4 ± 0.2 1
4BP-TQS 4.2 ± 0.3 5.2 ± 0.8 4.4 ± 0.3
NS-1738 N/A N/A 0.0 ± 0.0
TBS-346 N/A N/A 0.0 ± 0.0
TBS-516 N/A N/A 0.0 ± 0.0
TQS N/A N/A 0.0 ± 0.0
a7 L247T Acetylcholine 0.2 ± 0.01 2.1 ± 0.2 1
4BP-TQS 0.03 ± 0.003 2.3 ± 0.2 1.0 ± 0.1
NS-1738 0.8 ± 0.1 1.6 ± 0.2 0.8 ± 0.1
TBS-346 0.1 ± 0.04 1.7 ± 0.3 0.9 ± 0.1
TBS-516 0.2 ± 0.04 2.5 ± 0.3 1.1 ± 0.1
TQS 0.4 ± 0.1 1.7 ± 0.1 0.8 ± 0.1
a7 M260L Acetylcholine 63 ± 12 1.3 ± 0.1 1
4BP-TQS 2.5 ± 0.4 2.3 ± 0.4 9.0 ± 1.2
NS-1738 N/A N/A 0.0 ± 0.0
TBS-346 N/A N/A 0.0 ± 0.0
TBS-516 8.9 ± 2.5 1.8 ± 0.3 3.7 ± 0.6
TQS 12 ± 1.1 3.1 ± 0.4 1.5 ± 0.1
Data are means ± SEM from at least three independent experiments.
a Data for maximal currents (Imax) are normalised to the response to maximum
response to acetylcholine.
Fig. 6. The inﬂuence of a type I (NS-1738) and a type II PAM (TQS) on wild-type and
mutated (L247T or M260L) a7 nAChRs. A) Representative traces illustrating responses
with wild-type a7 nAChRs to acetylcholine (100 mM) and after the pre- and co-
application of either NS-1738 (10 mM; Left pair of traces) or TQS (30 mM; Right). B)
Representative traces illustrating responses with mutated (L247T) a7 nAChRs to
acetylcholine (10 mM) and to NS-1738 (10 mM; Left) or TQS (30 mM; Right). C) Repre-
sentative traces illustrating responses with mutated (M260L) a7 nAChRs to acetyl-
choline (100 mM) and NS-1738 (10 mM; Left) or TQS (30 mM; Right).
A. Chatzidaki et al. / Neuropharmacology 97 (2015) 75e8580As described earlier, we have identiﬁed a series of chemically
related TBS compounds that differ in their ability to alter desensi-
tisation of a7 nAChRs (Figs. 2 and 7A). We therefore examined the
inﬂuence of L247T and M260L mutations on the pharmacological
properties of these compounds. The reason for doing so was to
determine whether the differing effects of the L247T and M260L
mutations in converting TQS but not NS-1738 into agonists reﬂect a
consistent ability to discriminate between type I and type II PAMs.
When examined on a7 nAChRs containing the L247T mutation, all
ﬁve TBS compounds acted as agonists (Fig. 7B). Thus, it appears that
a feature of the L247T mutation is the conversion of all PAMs
examined (irrespective of their effect on desensitisation) into ag-
onists. In contrast, with a7 nAChRs containing theM260Lmutation,
strong agonist activity was observed only with the two TBS com-
pounds that had the greatest propensity to reduce desensitisation
in wild-type a7 nAChRs (TBS-516 and TBS-556; Fig. 7C). Therefore,
it appears that the M260L mutation has an effect on a7 nAChR
structure that can discriminate between PAMs that differ in their
inﬂuence upon desensitisation of wild-type a7 nAChRs. The a7-
selective antagonist MLA blocked responses to acetylcholine on
both L247T and M260L a7 nAChRs (Fig. 8). Similarly, MLA blocked
responses with all of the allosteric modulators that act as agonists
on these two mutated a7 nAChRs (representative data with TQS is
illustrated in Fig. 8). This is consistent with previous reports indi-
cating that, in addition to acting as a competitive antagonist of
acetylcholine, MLA can block activation of wild-type a7 nAChRs by
allosteric agonists such as 4BP-TQS via a non-competitive mecha-
nism (Gill et al., 2011).
It is notable that compounds that have no agonist effect on
M260L receptors (NS-1738, TBS-346, TBS-546 and TBS-345) and
also all of the compounds that are converted into agonists (TQS,
TBS-556 and TBS-516) retain their ability to potentiate agonist re-
sponses when co-applied with acetylcholine (Fig. 9). The fold
potentiation (determined on the basis of maximum peak response
compared to acetylcholine alone) was 2.5 ± 0.3 for NS-1738,
5.8 ± 3.1 for TQS, 2.8 ± 0.6 for TBS-346, 3.6 ± 0.6 for TBS-546,
6.2 ± 1.2 for TBS-345, 6.6 ± 1.0 for TBS-556 and 8.0 ± 3.1 for TBS-
516. In contrast, on L247T a7 nAChRs, upon which acetylcholine
acts as a non-desensitising agonist, (Fig. 7B) the amplitude of the
maximum response elicited by application of acetylcholine or by
allosteric ligands was very similar (Fig. 7B and Table 2). Co-
application of acetylcholine with the allosteric modulators onL247T a7 nAChRs did not potentiate or inhibit the response elicited
by acetylcholine alone.
For wild-type and mutated a7 nAChRs, concentration-
response curves were constructed for the orthosteric agonist
acetylcholine and for the allosteric agonist 4BP-TQS (Fig. 10). In
addition, agonist concentration-response curves were con-
structed for two type I PAMs (NS-1738 and TBS-346) and for two
type II PAMs (TBS-516 and TQS) (Fig. 10). In agreement with
previous studies (Gill et al., 2011), the allosteric agonist 4BP-TQS
generated larger maximal responses and a steeper Hill coefﬁcient
than the endogenous agonist acetylcholine on wild-type a7
nAChRs, whereas none of the PAMs tested (NS-1738, TBS-346,
TBS-516 or TQS) had any detectable agonist activity on wild-
type receptors (Fig. 10A and Table 2). In marked contrast, all of
the compounds tested (4BP-TQS, acetylcholine, NS-1738, TBS-
346, TBS-516 and TQS) generated broadly similar maximal re-
sponses and had similar Hill coefﬁcients on a7 nAChRs con-
taining the L247T mutation (Fig. 10B and Table 2). With a7
Fig. 7. Potentiation and agonist effects of TBS compounds on wild-type and mutated a7 nAChRs. A) Representative traces are shown illustrating responses from wild-type a7
nAChRs to acetylcholine (100 mM), together with responses to acetylcholine (100 mM) after pre- and co-application of TBS compounds (10 mM). To illustrate differences in the rate of
desensitsation, all responses on wild-type a7 nAChRs have been normalised to their peak response. B) Representative traces are shown illustrating agonist responses from a7
nAChRs containing the L247T (90) mutation to either acetylcholine (10 mM) or TBS compounds (10 mM). C) Representative traces are shown illustrating agonist responses from a7
nAChRs containing the M260L (220) mutation to either acetylcholine (100 mM) or TBS compounds (10 mM).
A. Chatzidaki et al. / Neuropharmacology 97 (2015) 75e85 81nAChRs containing the M260L mutation, the orthosteric and
allosteric agonists (acetylcholine and 4BP-TQS, respectively)
differed in their maximal responses and Hill coefﬁcients, much as
they do on wild-type a7 nAChRs (Fig. 10A and C). Also, with a7
nAChRs containing the M260L mutation, agonist responses were
observed with the two type II PAMs (TBS-516 and TQS) but not
with the two type I PAMs (NS-1738 and TBS-346). In addition, in
contrast to the L247T mutation, maximal responses with TBS-516
and TQS (the type II PAMs) were much closer to that observed
with acetylcholine than with 4BP-TQS (Fig. 10C and Table 2).
Previous studies have concluded that type I and type II PAMs,
despite their differing effects on desensitisation, can bind
competitively at a common allosteric transmembrane site (Collins
et al., 2011). Therefore, although the type I PAMs (NS-1738 and
TBS-346) did not act as agonists on a7 nAChRs containing the
M260L mutation (Figs. 6C and 10C) it is possible that they may
block the agonist response observed with type II PAMs on this
mutated receptor. When either of the type I PAMs (NS-1738 and
TBS-346 at 10 mM) was pre- and co-applied with either of the type
II PAMs (TQS or TBS-516 at 10 mM), an inhibition of agonistresponses was observed (Fig. 11AeD). If type I PAMs are causing
antagonism by binding competitively with type II PAMs on a7
nAChRs containing the M260L mutation, the antagonism would be
expected to be surmountable at high concentrations of the type II
PAM. We investigated this possibility by constructing an agonist
concentration-response curve to TQS in the absence and the
presence of a ﬁxed concentration of NS-1738 (Fig. 11E). The EC50
for TQS was 11.5 ± 1.1 mM (n ¼ 4) in the absence of NS-1738 and
45.4 ± 5.4 mM (n ¼ 5) in the presence of NS-1738 (Fig. 11E). This
corresponds to a signiﬁcant rightward shift (4.0-fold; t(7) ¼ 5.5,
P < 0.001) of the concentration-response curve in the presence of
NS-1738. However, the two curves had similar maxima (Fig. 11E),
which suggests that NS-1738 is blocking responses to TQS by a
competitive mechanism of action. A notable feature of the data is
that the concentrationeresponse curve is signiﬁcantly less steep
(t(7) ¼ 3.6, P < 0.01) in the presence of NS-1738 (a Hill coefﬁcient
of 1.5 ± 0.2), than in the absence of NS-1738 (3.1 ± 0.4), which may
be a consequence of NS-1738 acting as a potentiator of the TQS
response, at low TQS concentrations, when not all sites of the
receptor are occupied by TQS.
Fig. 9. Potentiation of acetylcholine responses by allosteric modulators on M260L a7
nAChRs. Representative traces are shown illustrating responses to acetylcholine
(100 mM) (left) together with responses from the same oocyte after pre- and co-
application of an allosteric modulator (10 mM) (right). Representative traces are
shown for NS-1738 (A), TQS (B), TBS-346 (C), TBS-546 (D), TBS-345 (E), TBS-556 (F) and
TBS-516 (G).
Fig. 8. Antagonism of agonist responses to acetylcholine and TQS responses on M260L
and L247T a7 nAChRs. A) Representative traces with M260L a7 nAChRs illustrating
initial agonist responses with acetylcholine (1 mM) or TQS (10 mM) (left), antagonism
by pre- and co-application of MLA (1 mM) (middle) and recovery in the absence of MLA
(right). B) Representative traces with L247T a7 nAChRs illustrating initial agonist re-
sponses with acetylcholine (10 mM) or TQS (3 mM) (left), antagonism by pre- and co-
application of MLA (1 mM) (middle) and recovery in the absence of MLA (right).
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A large number of ligands have been identiﬁed in recent years
that potentiate a7 nAChRs through an allosteric mechanism of ac-
tion (Arias, 2010; Bertrand and Gopalakrishnan, 2007; Faghih et al.,
2008; Mazurov et al., 2011; Williams et al., 2011). In large part, this
interest in a7-selective PAMs has been a consequence of the pos-
sibility that such compounds may have therapeutic use in thetreatment of various neurological and psychiatric disorders
(Haydar and Dunlop, 2010; Moaddel et al., 2007; Romanelli and
Gualtieri, 2003; Williams et al., 2011). Traditionally, a7-selective
PAMs have been characterised as either type I and type II,
depending on their effect on receptor desensitisation (Bertrand and
Gopalakrishnan, 2007). Type I PAMs increase peak agonist-evoked
currents, without altering receptor desensitisation, whereas type II
PAMs reduce the fast desensitisation of the a7 receptors. Evidence
is accumulating to indicate that both type I and type II PAMs can act
via a transmembrane site in a7 nAChRs (Collins et al., 2011; Young
et al., 2008). In addition, allosteric agonists have been identiﬁed
that appear to bind at a similar transmembrane site but, in doing so,
can activate a7 nAChRs in the absence of an orthosteric agonist (Gill
et al., 2013, 2012, 2011; Papke et al., 2014). Similarly, there is evi-
dence for agonist activation, via an allosteric transmembrane site,
for other pentameric ligand-gated ion channels (Amin and Weiss,
1993; Cully et al., 1996; Lansdell et al., 2015).
Fig. 10. Concentrationeresponse curves for the wild-type and mutated a7 nAChRs.
Data are shown from wild-type a7 nAChRs (A), a7 nAChRs containing the L247T (90)
mutation (B) and a7 nAChRs containing the M260L (220) mutation (C). Data are pre-
sented for a range of concentrations of acetylcholine (circles), the allosteric agonist
4BP-TQS (hexagons), the type II PAMs, TQS (squares) and TBS-516 (inverted triangles),
and the type I PAMs, NS-1738 (triangles) and TBS-346 (diamonds). Data are
means ± SEM of at least three independent experiments and are normalised to the
maximum acetylcholine response.
Fig. 11. Type I PAMs block agonist activity of TQS and TBS-516 on a7 nAChRs con-
taining the M260L mutation. Representative traces are shown, obtained by two-
electrode voltage-clamp recording in oocytes expressing a7 nAChRs containing the
M260L mutation, in which a type I PAM (NS-1738 or TBS-346) was pre applied for 10 s
and then co-applied with a type II PAM (TQS or TBS-516) (AeD). A) NS-1738 (10 mM)
completely blocked responses to TQS (10 mM). B) TBS-346 (10 mM) blocked responses
to TQS (10 mM) by 95.7 ± 1.1% (n ¼ 3). C) NS-1738 (10 mM) blocked responses to TBS-516
(10 mM) by 92.7 ± 2.3% (n ¼ 3). D) TBS-346 (10 mM) blocked responses to TBS-516
(10 mM) by 83.4 ± 4.1% (n ¼ 3). E) The agonist concentration-response curve for TQS
on a7 nAChRs containing the M260L mutation was shifted to the right in the presence
of NS-1738 (2 mM, pre-applied for 10 s and then co-applied with TQS). The antagonism
by NS-1738 was surmountable at high concentrations of TQS.
A. Chatzidaki et al. / Neuropharmacology 97 (2015) 75e85 83In the present study, ﬁve TBS compounds with close chemical
similarity to one another were synthesised and were demonstrated
to act as PAMs on a7 nAChRs but with range of effects on receptor
desensitisation. For example, we have identiﬁed members of this
series of compounds (such as TBS-346) that display effects on re-
ceptor desensitisation that are typical of type I PAMs, and others
(such as TBS-516) that are more typical of type II PAMs. In addition,
we have identiﬁed compounds with intermediate properties (such
as TBS-546, TBS-345 and TBS-556). With several of the TBS com-
pounds, there is evidence for two components to the rate of
desensitisation of the potentiated acetylcholine-evoked response,
but the proportion of the fast and slow component varied. Signif-
icantly, because of the similarity in chemical structure of these
compounds, we can conclude that these differences in their ability
A. Chatzidaki et al. / Neuropharmacology 97 (2015) 75e8584to inﬂuence receptor desensitisation is due solely to changes in
substitution at the 5-position of the triazole ring. These compounds
lack PAM activity on other nAChR subtypes (such as a4b2 and a3b4)
and on 5-HT3ARs, indicating that they are relatively selective po-
tentiators of a7 nAChRs. They do not displace [3H]-a-bungarotoxin
from its orthosteric-binding site on a7 nAChRs, supporting the
conclusion that these TBS compounds are allosteric modulators. In
addition, we have evidence from studies of an a7/5-HT3A subunit
chimera that is consistent with TBS compounds interacting with a
site within the transmembrane domain.
Although previous studies have demonstrated that the L247T
mutation can convert a type II PAM into an allosteric agonist (Gill
et al., 2011), we have extended this ﬁnding by demonstrating that
this is a feature conferred by the L247T mutation on type I PAMs,
type II PAMs and also on PAMs that can be considered to have in-
termediate (type I/II) properties. Based on structural studies from a
variety of pentameric ligand-gated ion channels, the amino acid
located at a position analogous to L247 (position 90) in the a7
nAChR is located close to the gate of the channel pore (Althoff et al.,
2014; Beckstein and Sansom, 2006; Hassaine et al., 2014; Miyazawa
et al., 1999). This may help to explain the profound effects that have
been observed when this amino acid is mutated. It seems plausible
that mutating this amino acid might disrupt the gate of the channel
and may result in a receptor where more of its conformations are
conducting. Indeed, a higher frequency of spontaneous openings
have been reported in receptors containing the L247T mutation
(Bertrand et al., 1997) as well as other changes in pharmacological
properties (Bertrand et al., 1992; Palma et al., 1996; Revah et al.,
1991). As has been discussed previously (Bertrand et al., 1997), it
is possible that the upward deﬂection in current responses in
response to the application of MLA to a7 L247T nAChRs (Fig. 8B) is a
consequence of it blocking spontaneously open channels. In
contrast to our ﬁndings with a7 nAChRs containing the L247T
mutation, the M260L mutation, which is located towards the
extracellular side of the TM2 domain (position 220), has a more
selective effect on PAMs. With this mutation, agonist activationwas
observed only with PAMs that substantially reduced the levels of
desensitisation in wild-type a7 nAChRs. This effect of the M260L
mutation is unlikely to be due to it preventing the binding of type I
PAMs because, even though type I PAMs are not converted into
agonists on the mutated receptor, they retain their PAM activity in
the presence of acetylcholine. In addition, type I PAMs block agonist
activation by type II PAMs in receptors containing the M260L mu-
tation. It is thought that type I PAMs increase peak current in the
presence of an agonist by facilitating the transition of the receptor
from the resting to open state upon activation by the agonist
without having an effect on receptor desensitisation. On the other
hand, type II PAMs signiﬁcantly reduce the fast desensitisation of
the a7 nAChRs and may allow receptor reactivation from the
desensitised state, perhaps by destabilising the desensitised state
or converting the desensitised state into a new conducting state.
As is illustrated in Fig. 5A, M260 is located near the extra-
cellular side of the TM2 domain, whereas L247 is located towards
the intracellular side (at positions 220 and 90, respectively). It is
also notable that the side chain of L247 is predicted to point
towards the ion channel pore, whereas that of M260 points to-
wards an intrasubunit cavity that has been proposed previously
as a binding site for allosteric modulators of a7 nAChRs (Gill
et al., 2011; Young et al., 2008). It is possible that these muta-
tions may facilitate direct receptor activation by PAMs by altering
the energy barrier for transitions between the closed, open and
desensitised states of the receptor. Direct allosteric activation
appears to be associated with a loss of rapid desensitisation. In
the case of the M260L mutation, which has no signiﬁcant effect
on desensitisation, allosteric activation occurs only with type IIPAMs (which themselves cause a loss of agonist-induced
desensitisation). In contrast, the L247T mutation, which itself
cause a loss of desensitisation, facilitates agonist activation by
type I PAMs (which do not alter receptor desensitisation). The
M260 residue is located towards the extracellular end of the TM2
domain in a region that has been referred to as the ‘M2-cap’
(Bafna et al., 2008). Previous studies have indicated that a stretch
of 10 amino acids this region can inﬂuence allosteric modulation
of an a7/5-HT3A subunit chimera (Bertrand et al., 2008). In
addition, studies of this region (180e280) on the a1 subunit of the
muscle-type nAChR, indicate that mutations in this region have
large effects on gating but smaller effects on channel conduc-
tance and desensitisation (Bafna et al., 2008). However, mutating
the isoleucine on the 220 position to a leucine (which corre-
sponds to M260 on the human a7 subunit) increased the
apparent rate for entry into long-lived desensitised states by
~10-fold (Bafna et al., 2008). It is plausible that this mutation in
the corresponding residue of the a7 subunit could have an effect
on the rate of receptor desensitisation, which could alter its
modulation by type II PAMs.
5. Conclusion
In conclusion, the availability of PAMs with properties that are
intermediate between those of classical type I and type II PAMs
increases the pharmacological diversity of this family of allo-
steric modulators. In addition, evidence for mutations located at
different positions in the transmembrane domain having distinct
effects on allosteric modulation helps to provide a greater insight
into the pharmacological diversity of these compounds. It is
hoped that the ability to develop and identify compounds with
differing effects on properties such as receptor desensitisation
may be useful in developing useful therapeutic tools for a range
of disorders.
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